Clinical Ophthalmology (Oct 2008)

A patient preference comparison of Azarga™ (brinzolamide/timolol fixed combination) vs Cosopt® (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension

  • Thomas K Mundorf,
  • Steven H Rauchman,
  • Robert D Williams,
  • Ricardo Notivol,
  • Brinzolamide/Timolol Preference Study Group

Journal volume & issue
Vol. 2008, no. Issue 3
pp. 623 – 628

Abstract

Read online

Thomas K Mundorf1, Steven H Rauchman2, Robert D Williams3, Ricardo Notivol4, Brinzolamide/Timolol Preference Study Group51Mundorf Eye Center, Charlotte, NC, USA; 2North Valley Eye Medical Group, Mission Hills, CA, USA; 3Taustine Eye Center, Louisville, KY, USA; 4Alcon, Barcelona, Spain; 5Ophthalmology Clinics, USAPurpose: To determine patient preference of and ocular discomfort with fixed combination brinzolamide/timolol compared with fixed combination dorzolamide/timolol.Methods: In a prospective, double-masked, randomized, active-controlled, crossover, multicenter study, patients received 1 drop of brinzolamide/timolol and dorzolamide/timolol in both eyes on consecutive days in random order. Ocular discomfort was rated 1 minute after instillation of each medication, and preference was noted on Day 2. Adverse events, if any, were solicited at each visit.Results: 127 subjects with ocular hypertension or open-angle glaucoma were included in the intent-to-treat analysis. Of the 106 subjects who expressed a drug preference, 79.2% preferred brinzolamide/timolol (p < 0.0001). Ocular discomfort scores were significantly higher with dorzolamide/timolol than brinzolamide/timolol (2.9 vs 1.4, respectively; p < 0.0001). Significantly more patients reported ocular pain and discomfort after dorzolamide/timolol instillation and transient blurred vision after brinzolamide/timolol instillation.Conclusions: Patients with ocular hypertension or open-angle glaucoma preferred the brinzolamide/timolol fixed combination over the dorzolamide/timolol fixed combination. This is likely due to the greater ocular discomfort associated with dorzolamide/timolol. The differences in preference, discomfort, and adverse events are likely attributable to formulation differences given the similarities of the active ingredients. Stronger patient preference for brinzolamide/timolol may lead to better therapeutic compliance.Keywords: brinzolamide/timolol, dorzolamide/timolol, patient preference, ocular discomfort, open-angle glaucoma or ocular hypertension